Hepatocellular Carcinoma Displays Distinct DNA Methylation Signatures with Potential as Clinical Predictors

Background Hepatocellular carcinoma (HCC) is characterized by late detection and fast progression, and it is believed that epigenetic disruption may be the cause of its molecular and clinicopathological heterogeneity. A better understanding of the global deregulation of methylation states and how they correlate with disease progression will aid in the design of strategies for earlier detection and better therapeutic decisions. Methods and Findings We characterized the changes in promoter methylation in a series of 30 HCC tumors and their respective surrounding tissue and identified methylation signatures associated with major risk factors and clinical correlates. A wide panel of cancer-related gene promoters was analyzed using Illumina bead array technology, and CpG sites were then selected according to their ability to classify clinicopathological parameters. An independent series of HCC tumors and matched surrounding tissue was used for validation of the signatures. We were able to develop and validate a signature of methylation in HCC. This signature distinguished HCC from surrounding tissue and from other tumor types, and was independent of risk factors. However, aberrant methylation of an independent subset of promoters was associated with tumor progression and etiological risk factors (HBV or HCV infection and alcohol consumption). Interestingly, distinct methylation of an independent panel of gene promoters was strongly correlated with survival after cancer therapy. Conclusion Our study shows that HCC tumors exhibit specific DNA methylation signatures associated with major risk factors and tumor progression stage, with potential clinical applications in diagnosis and prognosis.

[1]  Richard M. Simon,et al.  A Paradigm for Class Prediction Using Gene Expression Profiles , 2003, J. Comput. Biol..

[2]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[3]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[4]  I. Tischoff,et al.  DNA methylation in hepatocellular carcinoma. , 2008, World journal of gastroenterology.

[5]  Y. Hoshida,et al.  UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated with Hepatocellular Carcinoma in Japanese Patients with Hepatitis C Virus Infection , 2004, Clinical Cancer Research.

[6]  W. Tsai,et al.  Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA , 2007, Clinical Cancer Research.

[7]  A. Cassidy,et al.  Hypomethylation of retrotransposable elements correlates with genomic instability in non‐small cell lung cancer , 2009, International journal of cancer.

[8]  Kentaro Yamashita,et al.  Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. , 2006, Cancer cell.

[9]  S. Taylor-Robinson,et al.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. , 2008, World journal of gastroenterology.

[10]  B. Leggett,et al.  Review of genetic and epigenetic alterations in hepatocarcinogenesis , 2006, Journal of gastroenterology and hepatology.

[11]  M. Feitelson.  Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. , 2006, Cancer letters.

[12]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[13]  J. Issa,et al.  Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. , 2008, Carcinogenesis.

[14]  Moritoshi Kinoshita,et al.  Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci , 2002, Hepatology.

[15]  Chuan‐Mo Lee,et al.  UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis. , 2008, Biochemical and biophysical research communications.

[16]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Arora,et al.  Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. , 2007, Cancer research.

[18]  Jingde Zhu,et al.  Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis , 2003, Cell Research.

[19]  R. Simon,et al.  An investigation of two multivariate permutation methods for controlling the false discovery proportion , 2007, Statistics in medicine.

[20]  Richard Simon,et al.  A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..

[21]  S. Thorgeirsson,et al.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. , 2007, The Journal of clinical investigation.

[22]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[24]  Jingde Zhu.  DNA methylation and hepatocellular carcinoma. , 2006, Journal of hepato-biliary-pancreatic surgery.

[25]  W. Yeo,et al.  Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Flanagan,et al.  Host epigenetic modifications by oncogenic viruses , 2006, British Journal of Cancer.

[27]  J. Herman,et al.  Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. , 2003, The American journal of pathology.

[28]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[29]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[30]  R Simon,et al.  Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data , 2003, British Journal of Cancer.

[31]  S. Dudoit,et al.  Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .

[32]  V. Arango,et al.  Using the Gene Ontology for Microarray Data Mining: A Comparison of Methods and Application to Age Effects in Human Prefrontal Cortex , 2004, Neurochemical Research.

[33]  C. Ki,et al.  UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers , 2008, Cancer science.

[34]  Nita Ahuja,et al.  DNA methylation and environmental exposures in human hepatocellular carcinoma. , 2002, Journal of the National Cancer Institute.

[35]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[36]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. , 2003, The American journal of pathology.

[37]  Paolo Boffetta,et al.  Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. , 2009, Cancer research.

[38]  Jingde Zhu,et al.  Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis , 2002, BMC Cancer.

[39]  U. Meyer,et al.  Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. , 1996, Pharmacogenetics.

[40]  Chien-Jen Chen,et al.  High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1–DNA adduct levels in human hepatocellular carcinoma , 2002, Molecular carcinogenesis.

[41]  P. Bioulac-Sage,et al.  [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[42]  T. Hsiao,et al.  Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk , 2000, Gut.

[43]  Y. S. Kim,et al.  Prognostic Implications of and Relationship Between CpG Island Hypermethylation and Repetitive DNA Hypomethylation in Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[44]  S. Hirohashi,et al.  Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma , 2000, Hepatology.